Hueber, Wolfgang <br/><br/>
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.  [electronic resource] 

 -  Gut  Dec 2012 
 - 1693-700 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-3288 
<br/><br/><label>Standard No.: </label>10.1136/gutjnl-2011-301668  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Anti-Inflammatory Agents--therapeutic use<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Bayes Theorem<br/>Biomarkers--metabolism<br/>Crohn Disease--drug therapy<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Genetic Markers<br/>Humans<br/>Infusions, Intravenous<br/>Interleukin-17--antagonists & inhibitors<br/>Leukocyte L1 Antigen Complex--metabolism<br/>Male<br/>Middle Aged<br/>Polymorphism, Single Nucleotide<br/>Severity of Illness Index<br/>Treatment Failure<br/>Young Adult